Disease course patterns after discontinuation of bevacizumab: pooled analysis of randomized phase III trials.
about
Overcoming Hypoxia-Mediated Tumor Progression: Combinatorial Approaches Targeting pH Regulation, Angiogenesis and Immune DysfunctionTargeted anti-vascular therapies for ovarian cancer: current evidenceAnti-angiogenesis and metastasis: a tumour and stromal cell allianceBevacizumab treatment for advanced breast cancerMolecular mechanisms and clinical applications of angiogenesisTumor metastasis: molecular insights and evolving paradigmsNormalization of the vasculature for treatment of cancer and other diseases.Meta-analysis of the role of bevacizumab in extensive stage small cell lung cancer.Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions.Prognostic significance of AMPK activation in advanced stage colorectal cancer treated with chemotherapy plus bevacizumab.Neoadjuvant antiangiogenic therapy reveals contrasts in primary and metastatic tumor efficacy.Genetic targeting of sprouting angiogenesis using Apln-CreER.Sorafenib-based therapy in HER2-negative advanced breast cancer: Results from a retrospective pooled analysis of randomized controlled trials.Targeting angiogenesis in esophagogastric adenocarcinoma.Therapeutic antibodies against cancer.Antiangiogenic therapy: impact on invasion, disease progression, and metastasis.Reappraising antiangiogenic therapy for breast cancer.Cisplatin plus paclitaxel and maintenance of bevacizumab on tumour progression, dissemination, and survival of ovarian carcinoma xenograft models.Targeting angiogenesis in metastatic breast cancerDeciphering the Key Features of Malignant Tumor Microenvironment for Anti-cancer TherapyAnti-VEGF therapies in the clinicContrasting effects of sunitinib within in vivo models of metastasis.Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma.Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomised trial.Targeting prion-like protein doppel selectively suppresses tumor angiogenesis.The addition of bevacizumab to standard chemotherapy in breast cancer: which patient benefits the most?Efficacy and safety of extended use of platinum-based doublet chemotherapy plus endostatin in patients with advanced nonsmall cell lung cancerInterrogating tumor metabolism and tumor microenvironments using molecular positron emission tomography imaging. Theranostic approaches to improve therapeutics.Implications of vessel co-option in sorafenib-resistant hepatocellular carcinomaPost-bevacizumab Clinical Outcomes and the Impact of Early Discontinuation of Bevacizumab in Patients with Recurrent Malignant Glioma.Trials of bevacizumab in breast cancer--a safety review.Safety of bevacizumab in patients with metastatic breast cancer.Benefit-risk assessment of bevacizumab in the treatment of breast cancer.Patients with metastatic breast cancer using bevacizumab as a treatment: is there still a role for it?Progress in tumor vascular normalization for anticancer therapy: challenges and perspectives.Sorafenib in locally advanced or metastatic breast cancer.Anti-angiogenic drug discovery: lessons from the past and thoughts for the future.Modeling and predicting clinical efficacy for drugs targeting the tumor milieu.Angiogenesis-related agents in esophageal cancer.Why do targeted agents not work in the adjuvant setting in colon cancer?
P2860
Q26749333-1711B631-90E4-4F50-80F8-6308E5EB0375Q26830287-C7D76C0B-B31F-44F9-938A-12EE563789BDQ26862741-33040482-7C00-427E-B0F3-AAAC43EDED8AQ27027498-E2A6CD75-85AB-4602-AB30-014C05B28CBAQ29547314-0A990B66-9D46-4A6C-A684-D86984190E87Q29615908-D665D929-7BB5-4AE5-9F74-22B3E51148AAQ30471456-42DF47AE-3D7D-4E78-A4A7-D1739D911C31Q33443519-72EE85EE-0B33-4559-B0C4-94202C73DC75Q33770680-39288EFC-6766-4BE2-AF1F-40D19D565D6DQ33877467-FDA0F1E5-7EC3-4304-BA1E-C383EEDD3A8CQ34880943-862D6255-A2A2-447C-9DA8-C6622CE55673Q35023052-3B978EB8-DDD8-4A36-826D-829362EC73CAQ35190181-529258AC-56B4-4786-9D50-F0BE23FF823DQ35584958-AB4B055C-110E-4AD5-806D-0BA93A13EC60Q35908498-E86FAD36-9E5A-4C6A-AC2A-E134DE84A157Q35966757-66B2A554-0672-4DDE-A81E-7F50CFCAEE58Q35966766-776D3831-45C5-4100-95B1-7B2AE8AF2F34Q36089989-3C202277-2179-4AC5-9271-38396D05608BQ36182795-4EF41CCE-9E0E-4B17-8CA3-7B7F831309A6Q36284940-DAA923BD-6886-44C7-9D02-C9DB8AA38610Q36330281-FE46A1FC-450E-4F1A-8414-8B63BCF2E92EQ36394262-DF3B0D18-786C-4F63-AB2D-F8F02149FDDDQ36544101-9720F33D-A39B-4E50-AC65-A63AEE7055AFQ36680034-9C4AD964-67F3-4B66-ADA3-3F56AC3BECB6Q36737935-119AE5DC-B1EE-481F-A8FD-60CE5AE70B45Q36865945-56719B36-A5DB-4BF6-8044-3CCF81F5490FQ37116858-A868844E-EB59-40BB-ACB2-1F88A69715D6Q37236103-2A2EF610-0691-401D-825E-ECD17134BB2DQ37442540-16DA1306-352F-49F2-BA12-DA41D07B7F30Q37606640-B097D9C0-C3DC-4803-B510-7F6EFEFBA51AQ37887823-EDF06BDB-A5D9-43D8-8833-72E25FC9928FQ37903602-20AA1637-5D83-4C46-A547-F75EB6C8BE46Q37963955-05C17DAE-E2D2-4D61-9029-EB4F4FD04F1BQ37986561-2AEEF11E-2E54-468B-A564-2EB6A376241BQ37998372-C5A844DB-1973-4757-BB1D-1BC8791E6ABFQ38012156-C244304A-2586-48FC-B43B-974C2EE69CFCQ38020234-2B77933E-756E-4C8A-BCB0-FED8B894FC64Q38025261-9CE4CF24-C2E9-4F1E-A856-0F1F2B441547Q38031884-BB0868C7-84CD-4D8C-8D7D-9D6188092B28Q38062021-4262721B-04E0-4E9B-B694-CE49043345B4
P2860
Disease course patterns after discontinuation of bevacizumab: pooled analysis of randomized phase III trials.
description
2010 nî lūn-bûn
@nan
2010 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Disease course patterns after ...... f randomized phase III trials.
@ast
Disease course patterns after ...... f randomized phase III trials.
@en
Disease course patterns after ...... f randomized phase III trials.
@nl
type
label
Disease course patterns after ...... f randomized phase III trials.
@ast
Disease course patterns after ...... f randomized phase III trials.
@en
Disease course patterns after ...... f randomized phase III trials.
@nl
prefLabel
Disease course patterns after ...... f randomized phase III trials.
@ast
Disease course patterns after ...... f randomized phase III trials.
@en
Disease course patterns after ...... f randomized phase III trials.
@nl
P2093
P50
P356
P1476
Disease course patterns after ...... f randomized phase III trials.
@en
P2093
Barbara Mueller
David Miles
Florin Sirzén
Herbert Hurwitz
Jim Cassidy
P356
10.1200/JCO.2010.30.2794
P407
P577
2010-11-22T00:00:00Z